$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

$aldx Overview Financials Valuation SEC Filings Company Website

2016 Q3 Form 10-Q Financial Statement

#000119312516677524 Filed on August 10, 2016

Income Statement

Concept	2016 Q3	2016 Q2	2015 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.400M	$1.460M	$950.0K
YoY Change	11.11%	53.68%	-3.06%
% of Gross Profit
Research & Development	$3.380M	$2.835M	$1.249M
YoY Change	62.77%	126.93%	88.14%
% of Gross Profit
Depreciation & Amortization	$10.00K	$10.00K	$0.00
YoY Change	0.0%
% of Gross Profit
Operating Expenses	$3.380M	$2.835M	$1.249M
YoY Change	62.77%	126.93%	88.14%
Operating Profit	-$4.776M	-$4.297M	-$2.204M
YoY Change	43.11%	94.95%	33.86%
Interest Expense	$26.65K	$27.82K	$28.21K
YoY Change	-5.08%	-1.39%	-49.85%
% of Operating Profit
Other Income/Expense, Net	$1.138K	-$5.866K	-$28.21K
YoY Change	-104.05%	-79.21%	-105.52%
Pretax Income	-$4.780M	-$4.310M	-$2.230M
YoY Change	41.84%	93.27%	95.61%
Income Tax
% Of Pretax Income
Net Earnings	-$4.775M	-$4.303M	-$2.232M
YoY Change	41.88%	92.75%	96.64%
Net Earnings / Revenue
Basic Earnings Per Share			-$0.27
Diluted Earnings Per Share	-$383.3K	-$311.6K	-$0.27
COMMON SHARES
Basic Shares Outstanding	12.47M shares	9.713M shares	8.398M shares
Diluted Shares Outstanding			8.398M shares

Balance Sheet

Concept	2016 Q3	2016 Q2	2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$28.90M	$32.50M	$33.60M
YoY Change	-5.56%	-3.27%	192.17%
Cash & Equivalents	$14.57M	$17.61M	$33.57M
Short-Term Investments	$14.30M	$14.90M
Other Short-Term Assets	$300.0K	$300.0K	$300.0K
YoY Change	-50.0%	0.0%	0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$29.13M	$32.81M	$33.84M
YoY Change	-6.72%	-3.04%	186.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$65.69K	$75.03K	$40.87K
YoY Change	-25.74%	83.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$65.69K	$75.03K	$40.87K
YoY Change	-47.32%	83.58%
TOTAL ASSETS
Total Short-Term Assets	$29.13M	$32.81M	$33.84M
Total Long-Term Assets	$65.69K	$75.03K	$40.87K
Total Assets	$29.19M	$32.88M	$33.88M
YoY Change	-6.89%	-2.93%	186.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$733.6K	$823.3K	$629.3K
YoY Change	-1.35%	30.82%	13.18%
Accrued Expenses	$1.477M	$1.085M	$451.6K
YoY Change	134.26%	140.14%	113.7%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$426.5K	$310.2K	$310.2K
YoY Change		0.0%	-23.81%
Total Short-Term Liabilities	$2.637M	$2.373M	$1.391M
YoY Change	91.9%	70.59%	18.45%
LONG-TERM LIABILITIES
Long-Term Debt	$883.3K	$992.6K	$961.5K
YoY Change	-31.05%	3.23%	17.86%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$883.3K	$992.6K	$961.5K
YoY Change	-31.05%	3.23%	17.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.637M	$2.373M	$1.391M
Total Long-Term Liabilities	$883.3K	$992.6K	$961.5K
Total Liabilities	$3.520M	$3.366M	$2.353M
YoY Change	32.58%	43.06%	18.21%
SHAREHOLDERS EQUITY
Retained Earnings	-$72.65M	-$67.87M	-$50.88M
YoY Change	33.93%	33.4%	20.98%
Common Stock	$98.31M	$97.38M	$82.41M
YoY Change	18.54%	18.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.67M	$29.52M	$31.52M
YoY Change
Total Liabilities & Shareholders Equity	$29.19M	$32.88M	$33.88M
YoY Change	-6.89%	-2.93%	186.97%

Cashflow Statement

Concept	2016 Q3	2016 Q2	2015 Q2
OPERATING ACTIVITIES
Net Income	-$4.775M	-$4.303M	-$2.232M
YoY Change	41.88%	92.75%	96.64%
Depreciation, Depletion And Amortization	$10.00K	$10.00K	$0.00
YoY Change	0.0%
Cash From Operating Activities	-$3.510M	-$3.250M	-$1.610M
YoY Change	21.88%	101.86%	78.89%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$30.00K
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$570.0K	-$2.100M
YoY Change
Cash From Investing Activities	$560.0K	-$2.100M	-$30.00K
YoY Change	-1033.33%	6900.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$12.60M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-100.0K	12.81M	19.48M
YoY Change	900.0%	-34.24%	89.49%
NET CHANGE
Cash From Operating Activities	-3.510M	-3.250M	-1.610M
Cash From Investing Activities	560.0K	-2.100M	-30.00K
Cash From Financing Activities	-100.0K	12.81M	19.48M
Net Change In Cash	-3.050M	7.460M	17.84M
YoY Change	3.39%	-58.18%	90.19%
FREE CASH FLOW
Cash From Operating Activities	-$3.510M	-$3.250M	-$1.610M
Capital Expenditures	$0.00	$0.00	-$30.00K
Free Cash Flow	-$3.510M	-$3.250M	-$1.580M
YoY Change	24.47%	105.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12472521	shares
CY2016Q2	us-gaap	Securities For Reverse Repurchase Agreements SecuritiesForReverseRepurchaseAgreements	15500000
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67871854
CY2015Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33569784
CY2015Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.45
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	371422	shares
CY2015Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	539914
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	513301
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	31487714
CY2016Q2	us-gaap	Cash Cash	1060720
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	12472521	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12472521	shares
CY2016Q2	us-gaap	Assets Assets	32883548
CY2016Q2	us-gaap	Assets Current AssetsCurrent	32808521
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	97372402
CY2016Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	14940912
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17607522
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	12473
CY2016Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	823301
CY2016Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4703
CY2016Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	30436209
CY2016Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1084591
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2016Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	992625
CY2016Q2	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	0
CY2016Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	310185
CY2016Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q2	us-gaap	Liabilities Liabilities	3365824
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32883548
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2373199
CY2016Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1046802
CY2016Q2	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3169097
CY2016Q2	us-gaap	Share Price SharePrice	5.69
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	75027
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.91
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	29517724
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.34
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	779809	shares
CY2016Q2	us-gaap	Us Government Securities At Carrying Value USGovernmentSecuritiesAtCarryingValue	14936209
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	260087
CY2016Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	2282638
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1654482	shares
CY2016Q2	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	398094
CY2016Q2	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	173196
CY2016Q2	aldx	Accrued Deferred Offering Costs AccruedDeferredOfferingCosts	155122
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8527304
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1100000	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	7.00
CY2015Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.50
CY2015Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	211528	shares
CY2015Q1	us-gaap	Share Price SharePrice	20.00
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	9.33
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	394773
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	9712521	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	9712521	shares
CY2015Q4	us-gaap	Assets Assets	28204764
CY2015Q4	us-gaap	Assets Current AssetsCurrent	28088194
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83478851
CY2015Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	12941776
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14648866
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	9713
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	851160
CY2015Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8361
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1186429
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000	shares
CY2015Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1211310
CY2015Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	77546
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Liabilities Liabilities	3326445
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28204764
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2115135
CY2015Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	48657
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80334
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	24878319
CY2015Q1	aldx	Average Trading Volume Of Common Stock AverageTradingVolumeOfCommonStock	50000	shares
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	18707
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2423138	shares
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	25042480
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.98
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-58601884
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	497552
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1077330	shares
CY2015Q4	aldx	Accrued Research And Development Expense Current AccruedResearchAndDevelopmentExpenseCurrent	550323
CY2015Q4	aldx	Accrued General And Administrative Expense Current AccruedGeneralAndAdministrativeExpenseCurrent	192676
CY2015Q4	aldx	Deferred Offering Costs Noncurrent DeferredOfferingCostsNoncurrent	36236
CY2016Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12600000
CY2016Q2	us-gaap	Sale Of Stock Transaction Date SaleOfStockTransactionDate	2016-06-01
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1100000	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	7100000
CY2015Q1	invest	Investment Warrants Exercise Price InvestmentWarrantsExercisePrice	0.125
CY2015Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	211528	shares
CY2015Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	1900000
CY2015Q1	aldx	Redemption Price Of Warrants RedemptionPriceOfWarrants	0.001
CY2015Q1	aldx	Expiration Of Warrant ExpirationOfWarrant	P3Y
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.58
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1103661
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1926980
	us-gaap	Depreciation Depreciation	4002
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4368745
	us-gaap	Interest Paid InterestPaid	37730
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-56234
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-457085
	us-gaap	Net Income Loss NetIncomeLoss	-4368745
	us-gaap	Interest Expense InterestExpense	56234
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-31876
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	288052
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	34282
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4312511
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	28520046
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3445690
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31876
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28520046
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y9M7D
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2385531
	us-gaap	Share Based Compensation ShareBasedCompensation	1103661
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	7537396	shares
	aldx	Public And Private Offering Costs Incurred But Not Yet Paid PublicAndPrivateOfferingCostsIncurredButNotYetPaid	253134
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-113961
	dei	Entity Registrant Name EntityRegistrantName	ALDEYRA THERAPEUTICS, INC.
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	13954
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3066186	shares
	us-gaap	Interest Paid InterestPaid	39103
	us-gaap	Line Of Credit Facility Annual Principal Payment LineOfCreditFacilityAnnualPrincipalPayment	58160
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6182
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001341235
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>2.</b></td> <td valign="top" align="left"><b>BASIS OF PRESENTATION</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The accompanying interim unaudited condensed financial statements and related disclosures are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements and should be read in conjunction with the Company’s financial statements and related footnotes for the year ended December 31, 2015 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, which was filed with the Securities and Exchange Commission on March 30, 2016. The financial information as of June 30, 2016, the three and six months ended June 30, 2016 and 2015 is unaudited, but in the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair presentation of the financial position, results of operations and cash flows at the dates and for the periods presented of the results of these interim periods have been included. The balance sheet data as of December 31, 2015 was derived from audited financial statements. The results of the Company’s operations for any interim period are not necessarily indicative of the results that may be expected for any other interim period or for a full fiscal year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> On June 1, 2016, the Company closed an underwritten public offering in which it sold, an aggregate of approximately 2.8 million shares of common stock, including 360,000 shares sold in connection with the exercise in full by the underwriter of its option to purchase additional shares. The net proceeds of the offering, including the full exercise of the option, were approximately $12.6 million, after deducting the underwriting discounts and commissions and the other offering expenses payable by Aldeyra.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s management believes that its currently available resources, including amounts potentially available under its credit facility (Note 7), will provide sufficient funds to enable the Company to meet its expected obligations through approximately September of 2018 based on the Company’s current business plan. However, these amounts will not be sufficient for the Company to commercialize its product candidates or conduct any substantial, additional development requirements requested by the U.S. Food and Drug Administration (FDA). Additional funding may not be available to the Company on acceptable terms, or at all. If the Company is unable to secure additional capital, or meet financial covenants that could be implemented under the Company’s term loans in certain circumstances, it will be required to significantly decrease the amount of planned expenditures, and may be required to cease operations.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Curtailment of operations would cause significant delays in the Company’s efforts to introduce its products to market, which is critical to the realization of its business plan and the future operations of the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Recent Accounting Pronouncements</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-09 “Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”), to simplify the accounting for stock compensation. This update focuses on income tax accounting, award classification, estimating forfeitures, and cash flow presentation. The ASU becomes effective in 2017 for public companies and in 2018 for all other entities. Early adoption is permitted. Certain disclosures and detailed transition provisions apply. The Company does not believe that ASU 2016-09 will have a material impact on its financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). Under ASU 2016-2, an entity will be required to recognize right-of-use assets and lease liabilities on its balance sheet and disclose key information about leasing arrangements. ASU 2016-02 offers specific accounting guidance for a lessee, a lessor and sale and leaseback transactions. Lessees and lessors are required to disclose qualitative and quantitative information about leasing arrangements to enable a user of the financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. For public companies, ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, and requires a modified retrospective adoption, with early adoption permitted. The Company is in the process of evaluating the future impact of ASU 2016-02 on its financial position, results of operations and cash flows.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In November 2015, the FASB issued ASU No. 2015-17 “Income Taxes: Balance Sheet Classification of Deferred Taxes” (“ASU 2015-17”). To simplify the presentation of deferred income taxes, the amendments in this update require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This update is required to be effective for all public companies for annual periods beginning after December 15, 2016, and interim periods within those annual periods. Earlier application is permitted. The Company does not believe that ASU 2015-17 will have a material impact on its financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> In April 2015, the FASB issued ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). The amendments in ASU 2015-03 require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for the Company in the first quarter of fiscal year 2017, with early adoption permitted. ASU 2015-03 should be applied on a retrospective basis to each individual period presented. Upon implementation, the change in reporting debt issuance costs will require the Company to reclassify any deferred financing costs from an asset to a reduction of the reported debt balance. The application of ASU 2015-03 is not expected to have a material impact on the presentation of the Company’s financial position.</p> </div>
	dei	Document Period End Date DocumentPeriodEndDate	2016-06-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2958656
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.91
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1282687
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2917750
	us-gaap	Depreciation Depreciation	17117
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9256905
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-101838
	us-gaap	Net Income Loss NetIncomeLoss	-9269969
	us-gaap	Interest Expense InterestExpense	52853
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2111843
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27859
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-237465
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	13064
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9263787
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	9720033
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	12804981
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	13064
	us-gaap	Investment Income Interest InvestmentIncomeInterest	46671
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
	us-gaap	Nature Of Operations NatureOfOperations	<div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"> <tr> <td valign="top" width="4%" align="left"><b>1.</b></td> <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td> </tr> </table> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> Aldeyra Therapeutics, Inc. (the Company or Aldeyra), a Delaware corporation, is developing new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to naturally occurring toxic and pro-inflammatory chemical species known as aldehydes.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The Company’s principal activities to date include raising capital and research and development activities.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7734482
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11810
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12768745
	us-gaap	Use Of Estimates UseOfEstimates	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <b><i>Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with GAAP requires management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M15D
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6346037
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.00	pure
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.96
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y5M9D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.97
	dei	Trading Symbol TradingSymbol	ALDX
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	644648	shares
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	7620000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	17496	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1282687
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10167466	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
	aldx	Deferred Tax Assets Valuation Allowance Percentage DeferredTaxAssetsValuationAllowancePercentage	1.00	pure
	aldx	Number Of Incentive Plans NumberOfIncentivePlans	3	Incentive_Plan
	aldx	Public And Private Offering Costs Incurred But Not Yet Paid PublicAndPrivateOfferingCostsIncurredButNotYetPaid	155122
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice	4.59
	aldx	Interest Payment Period For Line Of Credit Facility InterestPaymentPeriodForLineOfCreditFacility	November 2013 through November 2014
	aldx	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod	50000	shares
	aldx	Line Of Credit Facility Maturity Month And Year LineOfCreditFacilityMaturityMonthAndYear	2016-11
	aldx	Deferred Offering Costs Paid By Cash DeferredOfferingCostsPaidByCash	-36236
CY2015Q4	us-gaap	Line Of Credit Facility Interest Rate During Period LineOfCreditFacilityInterestRateDuringPeriod	0.0650	pure
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2423138	shares
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	463588
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	954879
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2232186
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-28210
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-2232186
CY2015Q2	us-gaap	Interest Expense InterestExpense	28210
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2203976
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1249097
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8397713	shares
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3066186	shares
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.41
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	673581
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1462227
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4299712
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5866
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-4302616
CY2016Q2	us-gaap	Interest Expense InterestExpense	27817
CY2016Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	2904
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4296750
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	2904
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	21951
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2834523
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10622411	shares

Files In Submission

Name	View Source	Status
0001193125-16-677524-index-headers.html	Edgar Link	pending
0001193125-16-677524-index.html	Edgar Link	pending
0001193125-16-677524.txt	Edgar Link	pending
0001193125-16-677524-xbrl.zip	Edgar Link	pending
aldx-20160630.xml	Edgar Link	completed
aldx-20160630.xsd	Edgar Link	pending
aldx-20160630_cal.xml	Edgar Link	unprocessable
aldx-20160630_def.xml	Edgar Link	unprocessable
aldx-20160630_lab.xml	Edgar Link	unprocessable
aldx-20160630_pre.xml	Edgar Link	unprocessable
d201049d10q.htm	Edgar Link	pending
d201049dex1026.htm	Edgar Link	pending
d201049dex1027.htm	Edgar Link	pending
d201049dex311.htm	Edgar Link	pending
d201049dex312.htm	Edgar Link	pending
d201049dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx

2016 Q3 Form 10-Q Financial Statement

#000119312516677524 Filed on August 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX Aldeyra Therapeutics, Inc. Stock $aldx

2016 Q3 Form 10-Q Financial Statement

#000119312516677524 Filed on August 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALDX
Aldeyra Therapeutics, Inc. Stock $aldx